Background and objective: Extrapulmonary tuberculosis (EPTB) accounts for~15% of all TB patients, and TB pleural effusion is the second most common site of EPTB. The diagnosis of pleural TB is challenging due to the pauci-bacillary nature of the disease. Histopathology of thoracoscopically obtained pleural biopsy provides the highest diagnostic yield. The Xpert MTB/RIF assay (Xpert) is a PCR test that can identify both Mycobacterium tuberculosis (MTB) and rifampicin resistance. Currently, there is a lack of clarity regarding the value of Xpert on pleural tissue. We report our experience of using Xpert on thoracoscopic pleural biopsy samples. Methods: We retrospectively reviewed the records of patients who underwent thoracoscopy in our institution over a 1-year period. Relevant clinical details; indications; and results of tests on pleural tissue and fluid, including histopathology, mycobacterial cultures and Xpert, were extracted. Results: Of the 156 patients who underwent thoracoscopy, 73 (47%) had TB, 66 (42%) malignancy and 17 (11%) other conditions. Histopathology was diagnostic in all the 73 TB patients (100%). The yields of the microbiological tests against histopathology on thoracoscopic biopsy sample and pleural fluid were: pleural tissue Xpert 45%, pleural tissue culture 39%, pleural fluid culture 17% and pleural fluid Xpert 14%. Pleural tissue provided higher yields than fluid in both Xpert and culture (P < 0.05). Pleural tissue Xpert provided a higher yield than culture and substantially improved yield compared with closed pleural biopsy as we previously reported. Conclusion: Thoracoscopic pleural biopsy results in increased sensitivity on Xpert testing.
INTRODUCTION
Tuberculosis (TB) not only remains a global health problem, but it is evident from the WHO Global TB report 2016 that the TB epidemic is larger than previously estimated, with an estimated 10.4 million new cases and 1.4 million deaths, with an additional 0.4 million deaths from TB disease among patients with HIV. 1 Pulmonary TB is the most common form of TB, with extrapulmonary TB (EPTB) accounting for~15% of cases, but this estimate increases to~50% in high HIV prevalence settings. 2 Tuberculosis pleural effusion (TPE) is the second most common site of EPTB. 3 The diagnosis of pleural TB is challenging due to the pauci-bacillary nature of the biological samples and the need for diagnostic confirmation using invasive, expensive and time-consuming procedures, such as blind pleural biopsy, imaging-guided pleural biopsy and medical or surgical thoracoscopy. 4 Thoracoscopic pleural biopsy arguably has the highest yield in terms of confirmed diagnosis. 5 The Xpert MTB/RIF assay (Xpert; Cepheid, Sunnyvale, CA, USA) is a rapid, WHOendorsed, automated PCR test optimized for respiratory specimens that can detect both Mycobacterium tuberculosis (MTB) and rifampicin resistance. 6, 7 Given the limitations of available tests for the diagnosis of pleural TB, several studies have evaluated the 
SUMMARY AT A GLANCE
The role of pleural biopsy samples used in the Xpert MTB/RIF test (Xpert) to diagnose tuberculosis (TB) pleural effusion is unclear. We demonstrate an increase in diagnostic sensitivity when the Xpert test is performed on pleural tissue obtained by thoracoscopic biopsy, and it exceeds the yield from pleural fluid Xpert and mycobacterial culture of pleural tissue and fluid.
performance of Xpert using pleural fluid as a sample type. Overall, these studies show a sensitivity averaging around 22.7% against a composite reference standard (CRS). 8 However, the preferred specimen for the diagnosis of pleural TB is pleural tissue. We are aware of only a limited number of studies that have reported their results using Xpert on pleural tissue, mostly comprising a limited number of samples within larger studies. 7, 9, 10 We reported our experience using Xpert on pleural tissue that was obtained from closed pleural biopsy samples, and the yield was nil among the 96 patients of pleural TB, while the pleural fluid yields were 16% and 13.3% against two CRS.
11 We now report the yield from Xpert testing on larger pleural tissue samples from thoracoscopic biopsy.
METHODS
All patients who underwent medical thoracoscopy during the period 1 January 2015 to 31 December 2015, were included in the study. Data were generated retrospectively from the thoracoscopy database of the Department of Pulmonary Medicine, Christian Medical College, Vellore, a tertiary care teaching hospital in Southern India. This study was approved by the Christian Medical College, IRB (minutes no: 10406 (Retro) dated 30 November 2016). Patients with pleural effusion are referred for medical thoracoscopy when pleural fluid studies are non-diagnostic and MTB has not been demonstrated from a sputum sample. Medical thoracoscopy was performed using EVIS EXERA LTF-160 pleuravideoscope manufactured by Olympus (Tokyo, Japan), which is a semi-rigid/flexi-rigid thoracoscope. Pre-procedure thoracic ultrasound assessed the amount of pleural fluid, loculations and the most optimal site of entry. Pleural fluid was collected for cytology, cell counts and biochemical tests, including adenosine deaminase (ADA; Diazyme Laboratories, San Diego, CA, USA) and microbiological studies as appropriate. Biopsy was performed from the visualized abnormal areas, and in patients with no visualized pleural abnormality, it was taken from random areas in the parietal pleura. Normally, up to 10 biopsy pieces were obtained.
Around four to six pieces were collected in formalin (for histopathological examination), and at least two pieces each were collected in two saline tubes for mycobacterial cultures and Xpert test if there was a clinical likelihood of TB. One of these samples and a pleural fluid sample was processed using fluorescence smear microscopy and liquid cultures (Mycobacterium Growth Indicator Tube; Becton Dickinson, Sparks, MD, USA), and the second sample of both were used for Xpert testing. For Xpert testing, pleural tissue was finely ground and resuspended in 1 mL of sterile saline, and pleural fluid was centrifuged (3000 rpm for 15 min), and the supernatant was discarded, and the deposit was used. The steps of processing followed were as previously described. 12 
RESULTS
A total of 156 patients with undiagnosed pleural effusion underwent thoracoscopy during the period January 2015 and December 2015. The mean age of the patients was 50.9 AE 14.1 years (range: 17-78 years). The age--sex distribution of the subjects is described in Figure 1 . There were 105 males (67%) and 51 females (33%). A total of 97 (62%) patients had right-sided pleural effusion, and 59 (38%) had left-sided pleural effusion. None of them were HIV positive.
The final diagnosis of the subjects tested is tabulated in Table 1 . Approximately 73 (47%) patients had a diagnosis of TB, all of whom had a positive diagnosis by histopathology (100%). Sixty-six (42%) patients had malignancy (71% adeno, 5% squamous and 24% others). Among the 73 TB patients, pleural fluid Xpert was performed in 65 (89%) and pleural fluid culture in 69 (95%) patients. Pleural tissue Xpert was performed in 60 (82%) and tissue culture in 64 (88%) patients.
The diagnostic yields of the microbiological tests are shown in Tables 2 and 3 . The sensitivity of tissue Xpert (Table 4) .
DISCUSSION
To our knowledge, this is the first study to report the yield of Xpert from thoracoscopic pleural biopsy samples. Sehgal et al. 8 recently published a systemic review and meta-analysis on the performance of Xpert in the diagnosis of TPE. In their review, they commented that the drawback of the majority of currently available studies was the use of pleural fluid culture and CRS, which are poor reference standards for diagnosing TPE. They recommended that future studies should use pleural tissue histology as the reference standard. Our study is unique in having achieved this. We demonstrated the relatively high sensitivity of Xpert on pleural tissue obtained by thoracoscopy. To our knowledge, the only other article that had systematically studied the yield of Xpert in pleural tissue and fluid was performed by Du et al. 13 in Chinese patients. They also reported higher yields for tissue Xpert compared with fluid; the sensitivities being 85.5% and 43.6%, respectively. However, these figures were calculated using mycobacterial culture as gold standard, which explains the higher sensitivity they reported, compared with our study.
A systematic review by Maynard-Smith et al.
14
showed that a pooled sensitivity estimate using Xpert for diagnosing TB with lymph node tissue was as high as 0.96 (95% CI: 0.72-0.99) in comparison with other tissue samples (0.88, 95% CI: 0.77-0.95). The lowest pooled sensitivity estimate was that used for testing pleural fluid samples (0.34, 95% CI: 0.24-0.44.). Our earlier study 11 was based on closed pleural biopsy using a Tru-cut biopsy needle, and it demonstrated an abysmal yield with tissue Xpert test. The reasons may include small amount or even absence of pleural tissue as some passes may only manage to obtain skeletal muscle samples, and the limited tissue also had to be apportioned for histopathology and all microbiologic tests, including Xpert. Furthermore, as histopathology yield is superior to the microbiological yield from pleural tissue, there was a tendency to preferentially send the best samples to the pathology laboratory. It is likely that the amount of tissue sample is crucial to the yield of Xpert. It is well known that in other extrapulmonary samples like cerebrospinal fluid, increasing the volume of the specimen increases the diagnostic yield of TB. 15 Unlike closed pleural biopsy, in thoracoscopy, it is possible to obtain a large amount of tissue under vision from the site of pathology. While tubercular pleuritis (15) shows diffuse involvement of the parietal pleura, a biopsy from visibly abnormal pleura is still likely to result in higher microbiological yield, as with histopathology yield. The study also confirms the high yield of thoracoscopic pleural histopathology for the diagnosis of TB, which is well known. 5 In this series, the yield was 100%, and none of the microbiological tests were positive in any of the patients on whom histopathology was negative, nor were any of these patients given anti-TB treatment on the basis of clinician's judgement.
What then is the additional benefit of testing the pleural tissue for Xpert in a high TB prevalence setting, compared with histopathology alone? While granulomatous inflammation in pleural tissue is almost invariably due to TB in our patient population, in rare situations, other pathologies may present this way. Xpert positivity will therefore increase the confidence in the diagnosis of TB, and more importantly, it will facilitate the early diagnosis of multidrug-resistant TB. Drug-resistant pleural TB is not a rarity any longer in high TB prevalence setting. A positive Xpert result may be particularly invaluable in two situations: a report of rifampicin-resistant TB in the early commencement of multidrug-resistant TB (MDRTB) treatment and a report of rifampicin-sensitive TB when the clinician faces a paradoxical worsening of pleural effusion. In the latter, anti-tubercular therapy could be continued unchanged without fear of failure. Furthermore, Xpert results may be known within a couple of hours of the thoracoscopy procedure, as compared with 3-5 days in the case of histopathology. This helps the clinician commence anti-tubercular therapy, often on the same day, and remove the intercostal tube, resulting in earlier discharge of the patient and cost saving. In high TB prevalence settings, if there is ambiguity about the diagnosis of malignancy, pleurodesis is not performed during the thoracoscopy procedure and is deferred until histopathological confirmation is made. Thus, when the Xpert test is negative, the likelihood of malignancy increases, and the clinician could leave the intercostal tube in place until the histopathology report is ready in order to facilitate the performance of pleurodesis through the intercostal drainage (ICD) if the biopsy confirms malignancy. Furthermore, our study showed that, in 15% of the patients, culture from both fluid and tissue samples was negative, while Xpert was positive, providing the opportunity to assess their MDR status.
Our study has the following limitations. While thoracoscopy is now being increasingly performed outside the operating rooms (in bronchoscopy suites) and has been shown to be safe and well tolerated, it is more invasive and should be performed only in the appropriate clinical context, when sputum acid fast bacilli (AFB) smears/ Xpert and pleural fluid studies including ADA, are inconclusive. Furthermore, the study is retrospective, and so, a prospective study may provide more accurate information on the yield of Xpert on pleural tissue and fluid.
This study has demonstrated that pleural tissue from thoracoscopic pleural biopsy is a good sample for Xpert testing, improves microbiological diagnosis and provides the opportunity to ascertain MDR status. The yield from pleural fluid is more modest when compared with pleural tissue. For optimal results, both pleural tissue and fluid should be sent for Xpert as well as mycobacterial culture tests.
